Table 1 Primary and secondary outcomes of the study
Outcome | Metric | Time point/period |
|---|---|---|
Primary | ||
 Occurrence of ovarian cancer (primary or metastatic) | Incidence | 36 months |
 Number needed to treat to prevent one case of ovarian cancer (primary or metastatic) | NNT | 36 months |
Secondary | ||
 Disease-free survival | DFS | 36 months |
 Number needed to treat with PSO to prevent one case of ovarian cancer (primary or metastatic) | NNT | 36 months |
 Surgery-related morbidity of PSO | Number | 36 months |
 Subsequent intra-abdominal relapse pattern in the non-PSO group | Number | 36 months |
 Abnormal ovaries found during surgery | Number | During surgery |
 Incidence of ovarian (micro)metastatic disease | Incidence | 36 months |
 Quality of life (EORT QLQ-C30 and EORTC QLQ-CR29) | SUM score | Baseline, 3-, 12-, 24- and 36 months |
 Repeat surgery for complications (i.e. adhesions) | Numbers | 36 months |
 Long-term overall survival | OS in days | 60 months |
 Preference for PSO | Numbers | 36 months |
 Reversal of decision | Numbers | 36 months |
 Baseline characteristics | Numbers | Before surgery |
Other parameters | ||
 Type of surgery | Number per type of surgery | During surgery |
 Operation duration | Minutes | During surgery |
 Blood loss | Milliliters | During surgery |
 Pre- and postoperative treatment strategies | Number per type of treatment strategy | Before surgery and 36 months |